SEC Comment Letter for Vistagen Therapeutics, Inc. (VTGN) (CIK 0001411685) (VTGN) — Apr 7, 2020
Vistagen Therapeutics, Inc. (VTGN) (CIK 0001411685)
Date: April 7, 2020 · CIK: 0001411685 · Accession: 0000000000-20-002992
AI Filing Summary & Sentiment
File numbers found in text: 333-237514
Letter
April 6, 2020 Shawn K. Singh, J.D. Chief Executive Officer VistaGen Therapeutics, Inc. 343 Allerton Avenue South San Francisco, CA 94080 Re:VistaGen Therapeutics, Inc. Registration Statement on Form S-1 Filed March 31, 2020 File No. 333-237514 Dear Mr. Singh: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jessica R. Sudweeks, Esq.
Show Raw Text
April 6, 2020
Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, CA 94080
Re:VistaGen Therapeutics, Inc.
Registration Statement on Form S-1
Filed March 31, 2020
File No. 333-237514
Dear Mr. Singh:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jessica R. Sudweeks, Esq.